07:00 , Apr 18, 2005 |  BC Week In Review  |  Clinical News

Clioquinol: Phase II/III discontinued

PBT will not initiate the Phase II/III PLACQUE trial to treat AD because of di-iodo impurities found during the clinical manufacturing process. The company believes the impurities are responsible for side effects and mutagenicity. Attempts...
07:00 , Oct 18, 2004 |  BC Week In Review  |  Clinical News

PBT-1: Phase II data

Data from the 48-week open-label CQADEX extension of the previously reported 36-week Phase II CQAD trial in 9 evaluable patients showed a decline of 8 points in ADAS-Cog scores compared to the predicted decline of...
07:00 , Apr 26, 2004 |  BC Week In Review  |  Clinical News

PBT-1: Phase II updated data

Results from a 48-week extension of a previously reported 36-week Phase II trial showed that PBT-1 slowed decline in cognitive function. The longer-term treatment was well tolerated. Data were presented at the International Springfield/Montreal Symposium...
08:00 , Dec 22, 2003 |  BC Week In Review  |  Clinical News

PBT-1 clioquinol: Phase II

In an Australian Phase II trial in 36 patients, PBT-1 improved cognitive performance and reduced serum amyloid levels compared to placebo. Patients with higher ADAS-cog scores showed an average deterioration in score at 24 weeks...